SCHEMBL45878

SCHEMBL45878

CCc1cc(C)cc(C(C)(C)C)c1O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPA5 P11021 2/20 0.75
SMN1; SMN2 Q16637 5/20 0.72
CYP2C9 P11712 4/20 0.72
CYP2C19 P33261 4/20 0.72
HIF1A Q16665 4/20 0.72
ALDH1A1 P00352 4/20 0.65
CA2 P00918 3/20 0.65
POLB P06746 1/20 0.65
TYR P14679 1/20 0.65
CYP2D6 P10635 3/20 0.64
HSD17B10 Q99714 1/20 0.64
CA1 P00915 2/20 0.45
CYP1A2 P05177 3/20 0.44
LMNA P02545 2/20 0.43
RECQL P46063 1/20 0.43
GLRA3 O75311 1/20 0.42
GLRB P48167 1/20 0.42
MEN1 O00255 2/20 0.41
TSHR P16473 2/20 0.41
KMT2A Q03164 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30123824 1.00 HSPA5 (0.75) HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A
SCHEMBL29558774 0.86 HSPA5 (0.78) HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A
SCHEMBL29351672 0.86 HSPA5 (1.00) HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A
SCHEMBL29415372 0.86 HSPA5 (1.00) HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A
SCHEMBL34162 0.86 HSPA5 (1.00) HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A
SCHEMBL2230912 0.86 HSPA5 (0.78) HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A
SCHEMBL17500063 0.85 HSPA5 (0.70) HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A
SCHEMBL1174207 0.85 HSPA5 (0.55) HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A
SCHEMBL11247674 0.84 CYP2C9 (1.00) HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A
SCHEMBL29357108 0.84 CYP2C9 (1.00) HSPA5SMN1; SMN2CYP2C9CYP2C19HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115444917-B Traditional Chinese medicine composition and traditional Chinese medicine cream for treating eczema, and preparation methods and application thereof 新疆医科大学第四附属医院 2024-05-24 CN claimed
CN-115444917-A Traditional Chinese medicine composition and traditional Chinese medicine cream for treating eczema as well as preparation method and application of traditional Chinese medicine cream 新疆医科大学第四附属医院 2022-12-09 CN claimed
CN-108079349-B Large-area factory building sterilization and disinfection device 浙江泰林生物技术股份有限公司 2020-10-09 CN claimed
CN-115444917-B Traditional Chinese medicine composition and traditional Chinese medicine cream for treating eczema, and preparation methods and application thereof 新疆医科大学第四附属医院 2024-05-24 CN disclosed
US-20240026124-A1 USE OF DIEUGENOL, OLIGOMERS AND/OR POLYMERS OF EUGENOL FOR STABILIZING ORGANIC MATERIALS, STABILIZED PLASTICS COMPOSITION, STABILIZER COMPOSITION AND METHOD FOR STABILIZING ORGANIC MATERIALS Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2024-01-25 US disclosed
WO-2023108588-A1 PROCESS FOR PRODUCING CABLE WITH INSULATION LAYER DOW GLOBAL TECHNOLOGIES LLC (US) 2023-06-22 WO disclosed
WO-2023108586-A1 OLEFIN/SILANE INTERPOLYMER COMPOSITIONS WITH EXCELLENT THERMAL OXIDATION RESISTANCE DOW GLOBAL TECHNOLOGIES LLC (US) 2023-06-22 WO disclosed
CN-115444917-A Traditional Chinese medicine composition and traditional Chinese medicine cream for treating eczema as well as preparation method and application of traditional Chinese medicine cream 新疆医科大学第四附属医院 2022-12-09 CN disclosed
CN-108079349-B Large-area factory building sterilization and disinfection device 浙江泰林生物技术股份有限公司 2020-10-09 CN disclosed
US-10351771-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2019-07-16 US disclosed
CN-105142605-B 1, 2-alkane polyol-containing composition 大阪有机化学工业株式会社 2018-06-08 CN disclosed
US-8268381-B2 Methods and systems for coating a medical device ALLACCEM, INC. (US) 2012-09-18 US disclosed
US-8067403-B2 Methods and systems for preparing an antimicrobial composition ALLACCEM, INC. (US) 2011-11-29 US disclosed
US-20110124824-A1 DISPERSION COMPOSITION, POLYMERIZABLE COMPOSITION, LIGHT-SHIELDING COLOR FILTER, SOLID-STATE IMAGE PICK-UP ELEMENT, LIQUID CRYSTAL DISPLAY DEVICE, WAFER LEVEL LENS, AND IMAGE PICK-UP UNIT FUJIFILM CORPORATION (JP) 2011-05-26 US disclosed
US-20110015300-A1 METHODS AND SYSTEMS FOR COATING A SURFACE ALLACCEM, INC. 2011-01-20 US disclosed
US-7713955-B2 Applying to a surface one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning ALLACCEM, INC. (US) 2010-05-11 US disclosed
US-20100016270-A1 BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS ALLACCEM, INC. 2010-01-21 US disclosed
US-20080207581-A1 Applying to a surface one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning ALLACCEM, INC. 2008-08-28 US disclosed
US-20080020127-A1 Methods and systems for coating a medical device ALLACCEM, INC. 2008-01-24 US disclosed
US-20080021212-A1 Methods and systems for preparing an antimicrobial composition ALLACCEM, INC. 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016270-A1 BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS PCSK9, HMGCR, CETP HSPA5 2151/4885SMN1; SMN2 1707/4885CYP2C9 274/4885
US-20080021212-A1 Methods and systems for preparing an antimicrobial composition DNMT1, TET2, POLR1C HSPA5 3123/4885SMN1; SMN2 1784/4885CYP2C9 3078/4885
US-20080207581-A1 Applying to a surface one or more bridged polycyclic compounds comprising at least two cyclic groups defined in part by quaternary ammonium moieties; microbiocides; self-cleaning DNMT1, TET2, CD14 HSPA5 3874/4885SMN1; SMN2 3889/4885CYP2C9 2484/4885
US-20110015300-A1 METHODS AND SYSTEMS FOR COATING A SURFACE DNMT1, TET2, DNMT3A HSPA5 3234/4885SMN1; SMN2 1791/4885CYP2C9 2746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.